Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2013

View Archived Issues

Agilent Technologies partners with University of Queensland on oral cancer research

OraSure terminates assay collaboration with Roche Diagnostics

Single Cell Technology and AB Biosciences to identify therapeutic antibodies

GE Healthcare develops Affibody-based radiotracer to assess HER2 status

In vivo characterization of a potent mechanism-based therapeutic agent

Eisai joins tuberculosis drug accelerator partnership

Summit and the University of Oxford to develop treatments for DMD

E39 is well tolerated in patients with endometrial and ovarian cancer

Sanofi presents promising in vivo results for PDE-78INH

Achaogen discloses new agents for bacterial infections

AbbVie patents novel Nampt inhibitors for cancer and other disorders

EMA grants accelerated assessment to faldaprevir

Researchers in Luxembourg synthesize novel compound for infections

CleveXel and Dynamix to develop new treatment for rheumatoid arthritis

Bayer Schering Pharma discloses new chymase inhibitors

Takeda Pharmaceutical divulges new MCH1 receptor antagonists for obesity

VMY-2-109 treatment leads to reduction in nicotine self-administration in vivo

Nanovi secures funding to support development of BioXmark

FDA approves new delayed-release tablet formulation of posaconazole

Lytix Biopharma enrolls first patient in study of LTX-315

FDA accepts Targiniq ER NDA for review

Genmab reaches milestone in Janssen Biotech collaboration

Merrimack and Actavis form nanotechnology collaboration

QRxPharma refiles MoxDuo NDA

Novartis describes malate salts of diazaspiro ghrelin receptor agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...